Best Practice & Research Clinical Endocrinology & Metabolism
5Non-alcoholic fatty liver disease and risk of type 2 diabetes
Introduction
Non-alcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis not caused by excess use of alcohol (>20 g/day in women, >30 g/day in men), viruses such as hepatitis B or C, autoimmune hepatitis, use of hepatotoxic drugs or other compounds, or rare genetic forms [1]. It covers a range of conditions from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is currently the most common liver disorder with an estimated worldwide prevalence of 25% [2]. Depending on the method of diagnosis, 65–87% of patients with type 2 diabetes (T2DM) have NAFLD ∗[3], [4]. NAFLD is the second most common cause of being on a waiting list for a liver transplant in the US [5] and the most common cause of hepatocellular carcinoma (HCC) in both US [6] and UK [7].
The metabolic/insulin resistance syndrome is a well-established predictor of T2DM, although overt hyperglycemia only develops in those whose beta-cells fail to sustain hyperinsulinemia in the face of insulin resistance [8]. The liver is the site of production of glucose and very low-density lipoprotein (VLDL) -triglycerides. In subjects with ‘metabolic/obese NAFLD’, the liver is insulin resistant leading to overproduction of both glucose and VLDL [8]. Glucose in turn stimulates insulin secretion thereby inducing hyperinsulinemia. The increase in VLDL leads to lowering of the concentration of high-density lipoprotein (HDL) cholesterol. These changes are often observed in obese subjects, but are also observed independently of obesity [9]. NAFLD is thus closely linked to the pathogenesis of the metabolic syndrome raising the possibility that NAFLD predicts T2DM, even independently of obesity.
In addition to the association of NAFLD with the metabolic/insulin resistance syndrome, two common genetic variants increase the risk of NAFLD. A variant in the patatin-like phospholipase domain-containing 3 (PNPLA3) (rs738409[G], encoding I148M) confers to NAFLD susceptibility by increasing liver fat content, risk of inflammation, and fibrosis (‘PNPLA3 NAFLD’) ∗[10], ∗[11]. Genetic variation in the transmembrane 6 superfamily member 2 (TM6SF2) (rs58542926[T], encoding E167K) is also associated with liver fat accumulation and increased risk of NASH (‘TM6SF2 NAFLD’) ∗[12], [13]. Insulin resistance is not a characteristic of these two conditions [14], although genetic and metabolic causes of NAFLD may both exist in the same person [15].
The ensuing discussion is focused on reviewing studies which have examined whether NAFLD, diagnosed either by liver enzymes, ultrasonography, other imaging techniques, or by liver biopsy, predicts T2DM, and if so, whether this is observed independently of obesity and other established predictors of T2DM. We will also briefly comment on whether and why NAFLD should be screened for in the diabetes clinic.
Section snippets
Data sources and searches
This systematic review was performed as suggested by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) group [16]. We searched MEDLINE using the terms “fatty liver”, “diabetes”, and “ultrasound” for publications with NAFLD diagnosed by ultrasonography, “magnetic resonance spectroscopy” for those with NAFLD diagnosed by 1H-MRS, and “biopsy” for those with NAFLD diagnosed by biopsy. In addition, we used the terms “fatty liver”, “steatosis”, “liver enzymes”,
Study selection
The searches resulted in 1718 potentially relevant citations; NAFLD was defined using liver enzymes in 810, ultrasonography in 605, 1H-MRS in 247, and liver biopsy in 56. After screening the titles and abstracts of these citations, 54, 30, one and four, respectively, remained for further evaluation. Based on full-text judgment, we excluded i) 30 articles which were not prospective cohort studies, ii) 22 articles which did not adjust their analyzes for alcohol use or exclude other liver
Discussion
The data from the multiple available large studies document that NAFLD, diagnosed either by ultrasonography or elevated liver enzymes, predicts an increased risk of T2DM independently of age and obesity. These results raise the question as to whether the presence of NAFLD should be used in clinical practice to identify patients at risk for T2DM.
Ultrasonography-diagnosed NAFLD predicted T2DM in all studies, and in most studies after adjustment for potential confounders. These studies were,
Conflict of interest
None.
Acknowledgments
This study was supported by University of Helsinki, the Doctoral Programme in Clinical Research (S. Lallukka) and research grants (H. Yki-Järvinen) from the Academy of Finland, EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant no. 115372), EU H2020 EPoS 634413, the Sigrid Juselius Foundation, the EVO grant from the Finnish government, and personal grants (S. Lallukka) from the Diabetes Research, Biomedicum Helsinki, and Orion Research Foundations.
References (68)
- et al.
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States
Gastroenterology
(2015) - et al.
Obesity, insulin resistance, NASH and hepatocellular carcinoma
Semin Cancer Biol
(2013) - et al.
Hepatocellular cancer: the impact of obesity, Type 2 diabetes and a multidisciplinary team
J Hepatol
(2014) Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Lancet Diabetes Endocrinol
(2014)- et al.
Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease
J Hepatol
(2016) - et al.
The prevalence and etiology of elevated aminotransferase levels in the United States
Am J Gastroenterol
(2003) - et al.
Liver enzymes and risk of diabetes and cardiovascular disease: results of the firenze bagno a ripoli (FIBAR) study
Metabolism
(2008) - et al.
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors
Gastroenterology
(2009) - et al.
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity
J Lipid Res
(2009) - et al.
Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2
J Hepatol
(2015)
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis
Dig Liver Dis
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
J Hepatol
The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence
Clin Gastroenterol Hepatol
A position statement on NAFLD/NASH based on the EASL 2009 special conference
J Hepatol
European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease
J Hepatol
Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes
Hepatology
Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
Aliment Pharmacol Ther
Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms
Curr Diabet Rep
Liver fat in the metabolic syndrome
J Clin Endocrinol Metab
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Nat Genet
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease
Hepatology
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
Nat Genet
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Nat Commun
The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2
Semin Liver Dis
PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
BMJ
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association
Am J Gastroenterol
Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men
Diabetes Care
Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study
Hepatology
Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus
J Gastroenterol Hepatol
Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population
Am J Gastroenterol
The association of fatty liver and diabetes risk
J Epidemiol
Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up
Liver Int
Gamma-glutamyltransferase and diabetes–a 4 year follow-up study
Diabetologia
Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men
J Intern Med
Cited by (107)
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
2022, Cell MetabolismSYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis
2022, Cellular and Molecular Gastroenterology and HepatologyEffect of saffron supplementation on liver enzymes: A systematic review and meta-analysis of randomized controlled trials
2021, Diabetes and Metabolic Syndrome: Clinical Research and ReviewsLiver Stiffness Measurement is Useful in Predicting Type 2 Diabetes Mellitus Among Nonalcohol Fatty Liver Disease Patients
2024, Diabetes, Metabolic Syndrome and Obesity